Comparing Nymox Pharmaceutical (NYMX) & Arca Biopharma (ABIO)
Nymox Pharmaceutical (NASDAQ:NYMX) and Arca Biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Risk and Volatility
Nymox Pharmaceutical has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Arca Biopharma has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Nymox Pharmaceutical and Arca Biopharma, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arca Biopharma has a consensus target price of $2.00, suggesting a potential upside of 300.00%. Given Arca Biopharma’s higher probable upside, analysts plainly believe Arca Biopharma is more favorable than Nymox Pharmaceutical.
This table compares Nymox Pharmaceutical and Arca Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Nymox Pharmaceutical and Arca Biopharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nymox Pharmaceutical||$220,000.00||455.08||-$13.42 million||N/A||N/A|
|Arca Biopharma||N/A||N/A||-$18.49 million||N/A||N/A|
Nymox Pharmaceutical has higher revenue and earnings than Arca Biopharma.
Insider & Institutional Ownership
7.4% of Nymox Pharmaceutical shares are held by institutional investors. Comparatively, 15.7% of Arca Biopharma shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by insiders. Comparatively, 3.6% of Arca Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Arca Biopharma beats Nymox Pharmaceutical on 7 of the 10 factors compared between the two stocks.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Arca Biopharma Company Profile
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.